Literature DB >> 28776153

Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.

Geraldine J Ooi1,2,3, Paul R Burton4,5, Arul Earnest6, Cheryl Laurie4, William W Kemp7, Peter D Nottle5, Catriona A McLean8, Stuart K Roberts7, Wendy A Brown4,5.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), are endemic in obesity. We aimed to evaluate the diagnostic accuracy and reproducibility of a simple intraoperative visual liver score to stratify the risk of NASH and NAFLD in obesity and determine the need for liver biopsy.
METHODS: This is a prospective cohort study of obese adults undergoing bariatric surgery. The surgical team used a visual liver score to evaluate liver colour, size and surface. This was compared to histology from an intraoperative liver biopsy.
RESULTS: There were 152 participants, age 44.6 ± 12 years, BMI 45 ± 8.3 kg/m2. Prevalence of NAFLD was 70.4%, with 12.1% NASH and 26.4% borderline NASH. Single-visual components were less accurate than total composite score. Steatosis was most accurately identified (significant steatosis: AUROC 0.746, p < 0.05; severe steatosis: AUROC 0.855, p < 0.05). NASH was identified with moderate accuracy (AUROC 0.746, p = 0.001), with sensitivity 75% for a score ≥ 2. Stratification into low (≤ 1) and high-risk (≥ 4) scores accurately identified patients who should or should not have an intraoperative biopsy. Most patients with a normal-appearing liver did not have disease (94.4%). The structured visual assessment was quick and interobserver agreement was reasonable (κ = 0.53, p < 0.05).
CONCLUSIONS: A simple, structured tool based on liver appearance can be a useful and reliable tool for NAFLD risk stratification and identification of patients who would most and least benefit from a biopsy. A normal liver appearance reliably excludes significant liver disease, avoiding the need for liver biopsy in patients otherwise at high clinical risk of NASH.

Entities:  

Keywords:  Intraoperative liver biopsy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Visual appearance

Mesh:

Year:  2018        PMID: 28776153     DOI: 10.1007/s11695-017-2859-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  27 in total

1.  Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

Authors:  Guillaume Lassailly; Robert Caiazzo; Antoine Hollebecque; David Buob; Emmanuelle Leteurtre; Laurent Arnalsteen; Alexandre Louvet; Marie Pigeyre; Violeta Raverdy; Hélène Verkindt; Marie France Six; Carole Eberle; Alexandre Patrice; Sébastien Dharancy; Monique Romon; François Pattou; Philippe Mathurin
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 2.566

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 4.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

5.  Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study.

Authors:  David E Kleiner; Paul D Berk; Jesse Y Hsu; Anita P Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L Machado; Bruce M Wolfe; Steven H Belle
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

6.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Laparoscopy and histology in the diagnosis of chronic liver disease.

Authors:  R Jalan; D J Harrison; J F Dillon; R A Elton; N D Finlayson; P C Hayes
Journal:  QJM       Date:  1995-08

9.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

10.  The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.

Authors:  Sherene Shalhub; Anna Parsee; Scott F Gallagher; Krista L Haines; Chris Willkomm; Stephen G Brantley; Haim Pinkas; Lisa Saff-Koche; Michel M Murr
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.